Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
Barbanti PieroGabriella EgeoStefania ProiettiFlorindo d'OnofrioCinzia AuriliaCinzia FinocchiLaura Di ClementeMaurizio ZuccoAlberto DorettiStefano MessinaMassimo AutunnoAngelo RanieriAntonio CarnevaleBruno ColomboMassimo FilippiMiriam TasilloSteno RinalduzziPietro QuerzaniGiuliano SetteLorenzo ForinoFrancesco ZorodduMicaela RobottiAlessandro ValenzaCecilia CamardaLaura BorrelloMarco AguggiaGiovanna ViticchiCarlo TominoGiulia FiorentiniBianca OrlandoStefano BonassiPaola Torellinull nullPublished in: Neurology and therapy (2024)
This RWE study documents that long-term fremanezumab treatment is highly effective and remarkably well tolerated in subjects with HFEM or CM with multiple (> 3) therapeutic failures, even in the presence of concomitant medication overuse, psychiatric comorbidities, or both. The effectiveness-to-tolerability ratio appears to be better in RWE than in RCTs.